Breast Cancer
TAMENDOX
The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology in Stuttgart has developed a groundbreaking therapeutic approach for breast cancer patients for whom the effectiveness of the standard drug tamoxifen is limited. This innovative combination therapy, known as TAMENDOX, has been successfully tested in a clinical trial. The results have now been published in the renowned journal Clinical Cancer Research. The project was funded by the German Federal Ministry of Research, Technology and Space (BMFTR).
> Journal Website (closed access)